|
1
|
Wu CH, Lin YW, Wu TF, Ko JL and Wang PH:
Clinical implication of voltage-dependent anion channel 1 in
uterine cervical cancer and its action on cervical cancer cells.
Oncotarget. 7:4210–4225. 2016.PubMed/NCBI
|
|
2
|
Abu-Hamad S, Arbel N, Calo D, Arzoine L,
Israelson A, Keinan N, Ben-Romano R, Friedman O and Shoshan-Barmatz
V: The VDAC1 N-terminus is essential both for apoptosis and the
protective effect of anti-apoptotic proteins. J Cell Sci.
122:1906–1916. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Arbel N and Shoshan-Barmatz V:
Voltage-dependent anion channel 1-based peptides interact with
Bcl-2 to prevent antiapoptotic activity. J Biol Chem.
285:6053–6062. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shoshan-Barmatz V, De Pinto V,
Zweckstetter M, Raviv Z, Keinan N and Arbel N: VDAC, a
multi-functional mitochondrial protein regulating cell life and
death. Mol Aspects Med. 31:227–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Adams JM and Cory S: The Bcl-2 apoptotic
switch in cancer development and therapy. Oncogene. 26:1324–1337.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Del Gaizo Moore V, Brown JR, Certo M, Love
TM, Novina CD and Letai A: Chronic lymphocytic leukemia requires
BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2
antagonist ABT-737. J Clin Invest. 117:112–121. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oltersdorf T, Elmore SW, Shoemaker AR,
Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges
J, Hajduk PJ, et al: An inhibitor of Bcl-2 family proteins induces
regression of solid tumours. Nature. 435:677–681. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen S, Dai Y, Harada H, Dent P and Grant
S: Mcl-1 down-regulation potentiates ABT-737 lethality by
cooperatively inducing Bak activation and Bax translocation. Cancer
Res. 67:782–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mason KD, Vandenberg CJ, Scott CL, Wei AH,
Cory S, Huang DC and Roberts AW: In vivo efficacy of the Bcl-2
antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc
Natl Acad Sci USA. 105:17961–17966. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hann CL, Daniel VC, Sugar EA,
Dobromilskaya I, Murphy SC, Cope L, Lin X, Hierman JS, Wilburn DL,
Watkins DN and Rudin CM: Therapeutic efficacy of ABT-737, a
selective inhibitor of BCL-2, in small cell lung cancer. Cancer
Res. 68:2321–2328. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kutuk O and Letai A: Alteration of the
mitochondrial apoptotic pathway is key to acquired paclitaxel
resistance and can be reversed by ABT-737. Cancer Res.
68:7985–7994. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tagscherer KE, Fassl A, Campos B, Farhadi
M, Kraemer A, Böck BC, Macher-Goeppinger S, Radlwimmer B, Wiestler
OD, Herold-Mende C and Roth W: Apoptosis-based treatment of
glioblastomas with ABT-737, a novel small molecule inhibitor of
Bcl-2 family proteins. Oncogene. 27:6646–6656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gilormini M, Malesys C, Armandy E, Manas
P, Guy JB, Magné N, Rodriguez-Lafrasse C and Ardail D: Prefer ntial
targeting of cancer stem cells in the radiosensitizing effect of
ABT-737 on HNSCC. Oncotarget. 7:16731–16744. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Taiwan Cancer Registry Annual Report, .
Taiwan: Health promotion administration, ministry of health and
welfare. https://www.hpa.gov.tw/File/Attach/5191/File_6166.pdf
|
|
16
|
Marth C, Landoni F, Mahner S, McCormack M,
Gonzalez-Martin A and Colombo N; ESMO Guidelines Committee, :
Cervical cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 28 (Suppl 4):iv72–iv83. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Yang YB, Shen HM, Gu J, Li T and
Li XM: ABT-737 induces Bim expression via JNK signaling pathway and
its effect on the radiation sensitivity of HeLa cells. PLoS One.
7:e524832012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tomczak K, Czerwińska P and Wiznerowicz M:
The cancer genome atlas (TCGA): An immeasurable source of
knowledge. Contemp Oncol (Pozn). 19:A68–A77. 2015.PubMed/NCBI
|
|
19
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynecol
Obstet. 105:103–104. 2009. View Article : Google Scholar
|
|
20
|
Reers M, Smiley ST, Mottola-Hartshorn C,
Chen A, Lin M and Chen LB: Mitochondrial membrane potential
monitored by JC-1 dye. Methods Enzymol. 260:406–417. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elefantova K, Lakatos B, Kubickova J,
Sulova Z and Breier A: Detection of the mitochondrial membrane
potential by the cationic dye JC-1 in L1210 cells with massive
overexpression of the plasma membrane ABCB1 drug transporter. Int J
Mol Sci. 19(pii): E19852018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shah BP, Pasquale N, De G, Tan T, Ma J and
Lee KB: Core-shell nanoparticle-based peptide therapeutics and
combined hyperthermia for enhanced cancer cell apoptosis. ACS Nano.
8:9379–9387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou XL and Wang M: Expression levels of
survivin, Bcl-2, and KAI1 proteins in cervical cancer and their
correlation with metastasis. Genet Mol Res. 14:17059–17067. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kamaraddi S, Nayak A, Honnappa S and
Swarup A: Expression of Bcl-2 marker in premalignant lesions of
cervical cancer. Int J Reprod Contracept Obstet Gyneco. 15:965–969.
2016. View Article : Google Scholar
|
|
25
|
Fulda S, Galluzzi L and Kroemer G:
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov.
9:447–464. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kim BW, Cho H, Ylaya K, Kitano H, Chung
JY, Hewitt SM and Kim JH: Bcl-2-like Protein 11 (BIM) expression is
associated with favorable prognosis for patients with cervical
cancer. Anticancer Res. 37:4873–4879. 2017.PubMed/NCBI
|
|
27
|
Shoshan-Barmatz V, Zakar M, Rosenthal K
and Abu-Hamad S: Key regions of VDAC1 functioning in apoptosis
induction and regulation by hexokinase. Biochim Biophys Acta.
1787:421–430. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sugiyama T, Shimizu S, Matsuoka Y, Yoneda
Y and Tsujimoto Y: Activation of mitochondrial voltage-dependent
anion channel by apro-apoptotic BH3-only protein Bim. Oncogene.
21:4944–4956. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kroemer G, Galluzzi L and Brenner C:
Mitochondrial membrane permeabilization in cell death. Physiol Rev.
87:99–163. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Halestrap AP and Richardson AP: The
mitochondrial permeability transition: A current perspective on its
identity and role in ischaemia/reperfusion injury. J Mol Cell
Cardiol. 78:129–141. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li JY, Li YY, Jin W, Yang Q, Shao ZM and
Tian XS: ABT-737 reverses the acquired radioresistance of breast
cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res.
31:1022012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim KW, Moretti L, Mitchell LR, Jung DK
and Lu B: Combined Bcl-2/mammalian target of rapamycin inhibition
leads to enhanced radiosensitization via induction of apoptosis and
autophagy in non-small cell lung tumor xenograft model. Clin Cancer
Res. 15:6096–6105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lian J, Wu X, He F, Karnak D, Tang W, Meng
Y, Xiang D, Ji M, Lawrence TS and Xu L: A natural BH3 mimetic
induces autophagy in apoptosis-resistant prostate cancer via
modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum. Cell
Death Differ. 18:60–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Redza-Dutordoir M and Averill-Bate DA:
Activation of apoptosis signalling pathways by reactive oxygen
species. Biochim Biophys Acta. 1863:2977–2992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chipuk JE, Moldoveanu T, Lambi F, Parsons
MJ and Green DR: The BCL-2 family reunion. Mol Cell. 37:299–310.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ni Z, Wang B, Dai X, Ding W, Yang T, Li X,
Lewin S, Xu L, Lian J and He F: HCC cells with high levels of Bcl-2
are resistant to ABT-737 via activation of the ROS-JNK-autophagy
pathway. Free Radic Biol Med. 70:194–203. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Das DN, Naik PP, Mukhopadhyay S, Panda PK,
Sinha N, Meher BR and Bhutia SK: Elimination of dysfunctional
mitochondria through mitophagy suppresses benzo[a]pyrene-induced
apoptosis. Free Radic Biol Med. 112:452–463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Swiader A, Nahapetyan H, Faccini J,
D'Angelo R, Mucher E, Elbaz M, Boya P and Vindis C: Mitophagy acts
as a safeguard mechanism against human vascular smooth muscle cell
apoptosis induced by atherogenic lipids. Oncotarget. 7:28821–28835.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Peters GJ, Backus HH, Freemantle S, van
Triest B, Codacci-Pisanelli G, van der Wilt CL, Smid K, Lunec J,
Calvert AH, Marsh S, et al: Induction of thymidylate synthase as a
5-fluorouracil resistance mechanism. Biochim Biophys Acta.
1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bertoli C, Skotheim JM and de Bruin RA:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brookes S, Gagrica S, Sanij E, Rowe J,
Gregory FJ, Hara E and Peters G: Evidence for a CDK4-dependent
checkpoint in a conditional model of cellular senescence. Cell
Cycle. 14:1164–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Filippova M, Filippov V, Williams VM,
Zhang K, Kokoza A, Bashkirova S and Duerksen-Hughes P: Cellular
levels of oxidative stress affect the response of cervical cancer
cells to chemotherapeutic agents. Biomed Res Int. 2014:5746592014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
ATCC: CRL-1550, HTB-35, . 2005, http://www.atcc.org
|
|
44
|
Filippova M, Brown-Bryan TA, Casiano CA
and Duerksen-Hughes PJ: The human papillomavirus 16 E6 protein can
either protect or further sensitize cells to TNF: Effect of dose.
Cell Death Differ. 12:1622–1635. 2005. View Article : Google Scholar : PubMed/NCBI
|
